Loughan Ashlee R, Lanoye Autumn, Willis Kelcie D, Ravyts Scott G, Fox Amber, Zukas Alicia, Kim Youngdeok
Virginia Commonwealth University, Department of Neurology, USA.
Virginia Commonwealth University, Massey Cancer Center, USA.
Contemp Clin Trials Commun. 2023 Feb 1;32:101083. doi: 10.1016/j.conctc.2023.101083. eCollection 2023 Apr.
Sleep disturbance is among the most common symptoms endorsed by patients with primary brain tumor (PwPBT), with many reporting clinically elevated insomnia and poor management of their sleep-related symptoms by their medical team. Though Cognitive Behavioral Therapy for Insomnia (CBT-I) remains the front-line treatment for sleep disturbance, CBT-I has yet to be evaluated in PwPBT. Thus, it is unknown whether CBT-I is feasible, acceptable, or safe for patients with primary brain tumors.
PwPBT ( = 44) will enroll and participate in a six-week group-based CBT-I intervention delivered via telehealth. Feasibility will be based on pre-determined metrics of eligibility, rates and reasons for ineligibility, enrollment, and questionnaire completion. Acceptability will be measured by participant retention, session attendance, satisfaction ratings, and recommendation to others. Safety will be assessed by adverse event reporting. Sleep will be measured both objectively via wrist-worn actigraphy and subjectively via self-report. Participants will also complete psychosocial questionnaires at baseline, post-intervention, and three-month follow-up.
CBT-I, a non-pharmacological treatment option for insomnia, has the potential to be beneficial for an at-risk, underserved population: PwPBT. This trial will be the first to assess feasibility, acceptability, and safety of CBT-I in PwPBT. If successful, this protocol will be implemented in a more rigorous phase 2b randomized feasibility pilot with the aim of widespread implementation of CBT-I in neuro-oncology clinics.
睡眠障碍是原发性脑肿瘤患者(PwPBT)最常见的症状之一,许多患者报告临床上失眠情况严重,且其医疗团队对他们与睡眠相关症状的管理不善。尽管认知行为疗法治疗失眠(CBT-I)仍然是睡眠障碍的一线治疗方法,但尚未在原发性脑肿瘤患者中进行评估。因此,对于原发性脑肿瘤患者,CBT-I是否可行、可接受或安全尚不清楚。
44名原发性脑肿瘤患者将登记并参加为期六周的通过远程医疗提供的基于小组的CBT-I干预。可行性将基于预先确定的资格标准、不合格率和原因、登记情况以及问卷完成情况。可接受性将通过参与者留存率、课程出勤率、满意度评分以及向他人推荐情况来衡量。安全性将通过不良事件报告进行评估。睡眠将通过佩戴在手腕上的活动记录仪进行客观测量,并通过自我报告进行主观测量。参与者还将在基线、干预后和三个月随访时完成心理社会问卷。
CBT-I作为一种治疗失眠的非药物治疗选择,有可能对一个有风险且服务不足的人群——原发性脑肿瘤患者有益。这项试验将是首次评估CBT-I在原发性脑肿瘤患者中的可行性、可接受性和安全性。如果成功,该方案将在更严格的2b期随机可行性试点中实施,目的是在神经肿瘤诊所广泛实施CBT-I。